.png)
Ankylosing Spondylitis Market by Molecule Type and Route of Administration - Global Industry Analysis and Forecast To 2027
Published On : October 2018 Pages : 180 Category: Pharmaceuticals Report Code : HC101369
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Ankylosing Spondylitis Market by Molecule Type (Biologics, Biosimilars and Small molecules) and Route of Administration (Parenteral and Oral) - Global Industry Analysis And Forecast To 2027
Industry Outlook and Trend Analysis
Ankylosing spondylitis is a disorder that influences the spine; it is a form of arthritis. Ankylosing spondylitis infects (swells) the spine, ligaments and joints, while registering itself at a compound annual growth rate (CAGR) during the forecast period. The swollen effect leads to aching and rigidity in lower back and then move towards the upper spine, chest and neck. This disorder causes the bones (vertebrates) and joints to intact and become stiff and stubborn. X-ray is a way to detect the affected spine. Some signs of this disorder are fatigue, fever, loss of appetite and pain & rigidness in joints. This disorder mainly influences men more than women. Globally Ankylosing spondylitis counts not more than few percent and majorly seen in population in the age group of 18 to 45 also can occur at any age. The factors causing this disorder are unknown, but said to be hereditary i.e. transferred through genes.
Drivers and Restrains
There is no specific treatment available for this disorder, which is considered as driving factor for the market. The present therapy are only limited to minimizing the effect of Ankylosing Spondylitis. Other factors seen driving Ankylosing Spondylitis market are; increased number of people looking for solution for Ankylosing Spondylitis, rise in the R&D for finding specified therapy and rising number of population searching for suitable medicine to get rid of this disorder. Major restrains for Ankylosing Spondylitis market are; introduction of biosimilars and number of copyright issues (such as etanercept).
Segmentation
The Ankylosing Spondylitis Market is segmented on the basis of Molecule Type and Route of Administration -
- Based on Molecule Type the market is divided into: Biologics, Biosimilars and Small molecules.
- Based on Route of Administration the market is divided into: Parenteral and Oral.
Regional Outlook and Trend Analysis
Geographically, the Ankylosing Spondylitis Market is segmented into Europe, North America, Asia Pacific, Latin America, Middle East and Africa. Ankylosing Spondylitis Market is led by North America and pursued by Europe. It is because of use of new therapies, presence of enhanced health care sector & diagnosing equipment and more number of patients. Asia Pacific region is growing due to factors like; increased number of people diagnosed with Ankylosing Spondylitis, advancement in health care sector and increase in budget in health care sector by government. Latin America and Middle East & African regions are lacking in the market due to financial issues and scarcity of suitable therapy.
Competitive Insights
The key players in the Ankylosing Spondylitis Market are; Merck & Co. Inc., AbbVie Inc., Reliance Life Sciences Pvt. Ltd., Janssen Pharmaceuticals Inc., Momenta Pharmaceuticals Inc., Sandoz International GmbH, Pfizer Inc., Amgen Inc., Protalix BioTherapeutics, Inc., Regeneron Pharmaceuticals, and Celgene Corporation.
The Ankylosing Spondylitis Market is segmented as follows-
By Molecule Type:
- Biologics
- Biosimilars
- Small molecules
By Route of Administration:
- Parenteral
- Oral
Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Ankylosing Spondylitis Market, By Type, Estimates and Forecast, 2017-2027 ($Million)
o Biologics
o Biosimilars
o Small molecules
· Ankylosing Spondylitis Market, By Route of Administration, Estimates and Forecast, 2017-2027 ($Million)
o Parenteral
o Oral
· Ankylosing Spondylitis Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Ankylosing Spondylitis Market, By Country
o U.S. Ankylosing Spondylitis Market
o Canada Ankylosing Spondylitis Market
o Mexico Ankylosing Spondylitis Market
o Europe
§ Europe Ankylosing Spondylitis Market, By Country
o Germany Ankylosing Spondylitis Market
o UK Ankylosing Spondylitis Market
o France Ankylosing Spondylitis Market
o Russia Ankylosing Spondylitis Market
o Italy Ankylosing Spondylitis Market
o Rest of Europe Ankylosing Spondylitis Market
o Asia-Pacific
§ Asia-Pacific Ankylosing Spondylitis Market, By Country
o China Ankylosing Spondylitis Market
o Japan Ankylosing Spondylitis Market
o South Korea Ankylosing Spondylitis Market
o India Ankylosing Spondylitis Market
o Southeast Asia Ankylosing Spondylitis Market
o Rest of Asia-Pacific Ankylosing Spondylitis Market
o South America
§ South America Ankylosing Spondylitis Market
o Brazil Ankylosing Spondylitis Market
o Argentina Ankylosing Spondylitis Market
o Columbia Ankylosing Spondylitis Market
o Rest of South America Ankylosing Spondylitis Market
o Middle East and Africa
§ Middle East and Africa Ankylosing Spondylitis Market
o Saudi Arabia Ankylosing Spondylitis Market
o UAE Ankylosing Spondylitis Market
o Egypt Ankylosing Spondylitis Market
o Nigeria Ankylosing Spondylitis Market
o South Africa Ankylosing Spondylitis Market
o Rest of MEA Ankylosing Spondylitis Market
Table of Contents
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2027)
4.1.2. Canada Market States and Outlook (2017-2027)
4.1.3. Mexico Market States and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2027)
4.2.2. France Market States and Outlook (2017-2027)
4.2.3. UK Market States and Outlook (2017-2027)
4.2.4. Russia Market States and Outlook (2017-2027)
4.2.5. Italy Market States and Outlook (2017-2027)
4.2.6. Rest of Europe Market States and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2027)
4.3.2. Japan Market States and Outlook (2017-2027)
4.3.3. Korea Market States and Outlook (2017-2027)
4.3.4. India Market States and Outlook (2017-2027)
4.3.5. Southeast Asia Market States and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market States and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2027)
4.4.2. Argentina Market States and Outlook (2017-2027)
4.4.3. Columbia Market States and Outlook (2017-2027)
4.4.4. Rest of South America Market States and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2027)
4.5.2. United Arab Emirates Market States and Outlook (2017-2027)
4.5.3. Egypt Market States and Outlook (2017-2027)
4.5.4. Nigeria Market States and Outlook (2017-2027)
4.5.5. South Africa Market States and Outlook (2017-2027)
4.5.6. Turkey Market States and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market States and Outlook (2017-2027)
5. Ankylosing Spondylitis Market, By Molecule Type
5.1. Introduction
5.2. Global Ankylosing Spondylitis Revenue and Market Share by Molecule Type (2017-2027)
5.2.1. Global Ankylosing Spondylitis Revenue and Revenue Share by Molecule Type (2017-2027)
5.3. Biologics
5.3.1. Global Biologics Revenue and Growth Rate (2017-2027)
5.4. Biosimilars
5.4.1. Global Biosimilars Revenue and Growth Rate (2017-2027)
5.5. Small molecules
5.5.1. Global Small molecules Revenue and Growth Rate (2017-2027)
6. Ankylosing Spondylitis Market, By Route Of Administration
6.1. Introduction
6.2. Global Ankylosing Spondylitis Revenue and Market Share by Route Of Administration (2017-2027)
6.2.1. Global Ankylosing Spondylitis Revenue and Revenue Share by Route Of Administration (2017-2027)
6.3. Parenteral
6.3.1. Global Parenteral Revenue and Growth Rate (2017-2027)
6.4. Oral
6.4.1. Global Oral Revenue and Growth Rate (2017-2027)
7. Ankylosing Spondylitis Market, By Region
7.1. Introduction
7.2. Global Ankylosing Spondylitis Revenue and Market Share by Regions
7.2.1. Global Ankylosing Spondylitis Revenue by Regions (2017-2027)
7.3. North America Ankylosing Spondylitis by Countries
7.3.1. North America Ankylosing Spondylitis Revenue and Growth Rate (2017-2027)
7.3.2. North America Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Ankylosing Spondylitis by Countries
7.4.1. Europe Ankylosing Spondylitis Revenue and Growth Rate (2017-2027)
7.4.2. Europe Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Ankylosing Spondylitis by Countries
7.5.1. Asia-Pacific Ankylosing Spondylitis Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Ankylosing Spondylitis by Countries
7.6.1. South America Ankylosing Spondylitis Revenue and Growth Rate (2017-2027)
7.6.2. South America Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Ankylosing Spondylitis by Countries
7.7.1. Middle East and Africa Ankylosing Spondylitis Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Merck & Co. Inc.
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. AbbVie Inc.
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. Reliance Life Sciences Pvt. Ltd.
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Janssen Pharmaceuticals Inc.
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. Momenta Pharmaceuticals Inc.
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. Sandoz International GmbH
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. Pfizer Inc.
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. Amgen Inc.
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
8.9. Protalix BioTherapeutics, Inc.
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Revenue and Market Share
8.10. Regeneron Pharmaceuticals
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Revenue and Market Share
8.11. Celgene Corporation
8.11.1. Business Overview
8.11.2. Service Portfolio
8.11.3. Strategic Developments
8.11.4. Revenue and Market Share
9. Global Ankylosing Spondylitis Market Competition, by Manufacturer
9.1. Global Ankylosing Spondylitis Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Ankylosing Spondylitis Price By Region (2017-2017)
9.3. Top 5 Ankylosing Spondylitis Manufacturer Market Share
9.4. Market Competition Trend
10. Ankylosing Spondylitis Market Forecast (2017-2027)
10.1. Global Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2027)
10.2. Ankylosing Spondylitis Market Forecast by Regions (2017-2027)
10.2.1. North America Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.1.1. United States Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.1.2. Canada Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.1.3. Mexico Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2. Europe Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2.1. Germany Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2.2. France Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2.3. UK Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2.4. Russia Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2.5. Italy Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.2.6. Rest of Europe Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3. Asia-Pacific Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3.1. China Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3.2. Japan Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3.3. Korea Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3.4. India Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3.5. Southeast Asia Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.3.6. Rest of Asia-Pacific Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.4. South America Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.4.1. Brazil Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.4.2. Argentina Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.4.3. Columbia Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.4.4. Rest of South America Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5. Middle East and Africa Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.1. Saudi Arabia Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.2. United Arab Emirates Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.3. Egypt Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.4. Nigeria Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.5. South Africa Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.6. Turkey Ankylosing Spondylitis Market Forecast (2017-2027)
10.2.5.7. Rest of Middle East and Africa Ankylosing Spondylitis Market Forecast (2017-2027)
10.3. Ankylosing Spondylitis Market Forecast by Molecule Type (2017-2027)
10.3.1. Ankylosing Spondylitis Forecast by Molecule Type (2017-2027)
10.3.2. Ankylosing Spondylitis Market Share Forecast by Molecule Type (2017-2027)
10.4. Ankylosing Spondylitis Market Forecast by Route Of Administration (2017-2027)
10.4.1. Ankylosing Spondylitis Forecast by Route Of Administration (2017-2027)
10.4.2. Ankylosing Spondylitis Market Share Forecast by Route Of Administration (2017-2027)
List of Tables
List of Tables and Figures
Figure United States Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Ankylosing Spondylitis Revenue and Revenue Share by Molecule Type (2017-2018)
Figure Global Biologics Revenue and Growth Rate (2017-2018)
Figure Global Biosimilars Revenue and Growth Rate (2017-2018)
Figure Global Small molecules Revenue and Growth Rate (2017-2018)
Table Global Ankylosing Spondylitis Revenue and Revenue Share by Route Of Administration (2017-2018)
Figure Global Parenteral Revenue and Growth Rate (2017-2018)
Figure Global Oral Revenue and Growth Rate (2017-2018)
Table Global Ankylosing Spondylitis Revenue by Regions (2017-2018)
Figure North America Ankylosing Spondylitis Growth Rate (2017-2018)
Figure North America Ankylosing Spondylitis Revenue and Growth Rate (2017-2018)
Figure North America Ankylosing Spondylitis by Countries (2017-2018)
Figure North America Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2018)
Figure United States Ankylosing Spondylitis Growth Rate (2017-2018)
Figure United States Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Canada Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Mexico Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Europe Ankylosing Spondylitis Revenue and Growth Rate (2017-2018)
Figure Europe Ankylosing Spondylitis by Countries (2017-2018)
Figure Europe Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2018)
Figure Germany Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Germany Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Ankylosing Spondylitis Growth Rate (2017-2018)
Figure France Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Ankylosing Spondylitis Growth Rate (2017-2018)
Figure UK Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Russia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Italy Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Rest of Europe Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Asia-Pacific Ankylosing Spondylitis Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Ankylosing Spondylitis by Countries (2017-2018)
Figure Asia-Pacific Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2018)
Figure China Ankylosing Spondylitis Growth Rate (2017-2018)
Figure China Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Japan Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Korea Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Ankylosing Spondylitis Growth Rate (2017-2018)
Figure India Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Southeast Asia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Ankylosing Spondylitis Growth Rate (2017-2018)
Figure South America Ankylosing Spondylitis Revenue and Growth Rate (2017-2018)
Figure South America Ankylosing Spondylitis by Countries (2017-2018)
Figure South America Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Brazil Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Argentina Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Columbia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Rest of South America Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Middle East and Africa Ankylosing Spondylitis Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Ankylosing Spondylitis by Countries (2017-2018)
Figure Middle East and Africa Ankylosing Spondylitis Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Saudi Arabia Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Ankylosing Spondylitis Growth Rate (2017-2018)
Figure United Arab Emirates Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Egypt Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Nigeria Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Ankylosing Spondylitis Growth Rate (2017-2018)
Figure South Africa Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Turkey Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2017-2018)
Table Merck & Co. Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AbbVie Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Reliance Life Sciences Pvt. Ltd. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Janssen Pharmaceuticals Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Momenta Pharmaceuticals Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sandoz International GmbH Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Protalix BioTherapeutics, Inc. Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Regeneron Pharmaceuticals Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Celgene Corporation Ankylosing Spondylitis Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Ankylosing Spondylitis Market Share by Manufacturer
Figure Global Ankylosing Spondylitis Revenue and Market Share by Manufacturer
Table Global Ankylosing Spondylitis Price by Region (2017-2017)
Figure Top 5 Ankylosing Spondylitis Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Ankylosing Spondylitis Revenue (Millions USD) and Growth Rate (2018-2025)
Table Ankylosing Spondylitis Market Forecast by Regions (2018-2025)
Figure North America Ankylosing Spondylitis Market Forecast (2018-2025)
Figure United States Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Canada Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Mexico Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Europe Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Germany Ankylosing Spondylitis Market Forecast (2018-2025)
Figure France Ankylosing Spondylitis Market Forecast (2018-2025)
Figure UK Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Russia Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Italy Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Rest of Europe Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Asia-Pacific Ankylosing Spondylitis Market Forecast (2018-2025)
Figure China Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Japan Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Korea Ankylosing Spondylitis Market Forecast (2018-2025)
Figure India Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Southeast Asia Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Ankylosing Spondylitis Market Forecast (2018-2025)
Figure South America Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Brazil Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Argentina Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Columbia Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Rest of South America Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Middle East and Africa Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Saudi Arabia Ankylosing Spondylitis Market Forecast (2018-2025)
Figure United Arab Emirates Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Egypt Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Nigeria Ankylosing Spondylitis Market Forecast (2018-2025)
Figure South Africa Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Turkey Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Ankylosing Spondylitis Market Forecast (2018-2025)
Figure Global Ankylosing Spondylitis Forecast by Molecule Type (2018-2025)
Figure Global Ankylosing Spondylitis Market Share Forecast by Molecule Type (2018-2025)
Figure Global Ankylosing Spondylitis Forecast by Molecule Type (2018-2025)
Figure Global Ankylosing Spondylitis Forecast by Route Of Administration (2018-2025)
Figure Global Ankylosing Spondylitis Market Share Forecast by Route Of Administration (2018-2025)
Figure Global Ankylosing Spondylitis Forecast by Route Of Administration (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|